Evidence map›Paper›PMID 38418151›Full record

ArticleIn vivo (Athens, Greece)

Immunophenotypes and Tumor Immune Microenvironment in Hepatocellular Carcinoma With Macrotrabecular Massive and Vessels Encapsulating Tumor Clusters.

Jun Akiba, Masamichi Nakayama, Reiichiro Kondo, Hironori Kusano, Sachiko Ogasawara, Yutaro Mihara, Masahiko Tanigawa, Kana Tsutsui, Yuta Yano, Daiki Miyazaki and 7 more

Open access · diamondAbstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Jun AkibaDepartment of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan; akiba@med.kurume-u.ac.jp.
Masamichi NakayamaDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Reiichiro KondoDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Hironori KusanoDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Sachiko OgasawaraDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Yutaro MiharaDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Masahiko TanigawaDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Kana TsutsuiDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Yuta YanoDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Daiki MiyazakiDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Saeko TokisawaDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Toshiyuki MitsuhashiDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Hidetoshi NomuraDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Sakiko SanadaDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Hisamune SakaiDepartment of Surgery, Kurume University School of Medicine, Kurume, Japan.
Toru HisakaDepartment of Surgery, Kurume University School of Medicine, Kurume, Japan.
Hirohisa YanoDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Kurume University · JPKurume University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimRecently, vessels encapsulating tumor clusters (VETC) pattern and macrotrabecular massive (MTM) pattern of hepatocellular carcinoma (HCC) have been reported as aggressive histological types. These histological patterns showed an immunosuppressive tumor immune microenvironment (TIME). Since there have been no reports on the differences of these two subtypes simultaneously, this study examined the immunophenotypes and TIME of MTM-HCC and VETC-HCC immunohistochemically. PATIENTS AND

methodsSeventy-four cases of previously diagnosed HCC, including 32 MTM-HCCs, 21 VETC-HCCs, and 21 conventional HCCs, were enrolled in immunohistochemical analysis. We conducted immunohistochemical analysis.

resultsWe found that MTM-HCC showed less frequent expression of HepPar-1, which is one of the most common hepatocytic markers. In MTM-HCC, the frequency of high expression levels of Keratin19, carbonic anhydrase (CA) IX, and PD-L1 was higher compared to VETC-HCC and conventional HCC. PD-L1 expression was found in 34.4% of MTM-HCC, 0% of VETC-HCC, and 19.0% of conventional HCC. The rate of PD-L1 expression in MTM-HCC was significantly higher than the others (p=0.0015). PD-L1 expression was significantly associated with epithelial cell adhesion molecules and CA IX expression, which are representative markers of tumor stemness and hypoxic conditions, respectively. The CD8 infiltration in VETC-HCC was significantly lower than that in conventional HCC.

conclusionMTM-HCC had different immunophenotypes and TIMEs compared to HCC with the VETC pattern. Although both had immunosuppressive TIME, the elements forming TIME were quite different. To enhance the immune checkpoint inhibitor efficacy, changing TIME from a suppressive to an active form is essential.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsB7-H1 AntigenHumansRetrospective StudiesTumor MicroenvironmentB7-H1 AntigenimmunophenotypesMacrotrabecular hepatocellular carcinomatumor immune microenvironmentvessels encapsulating tumor clusters hepatocellular carcinoma

Identifiers

PMID38418151
PMCPMC10905475
OpenAlexW4392250857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.